 "bharat biotech, vaccine, coronavirus, covid-19, pharma, drugs, medicine")
Bharat Biotech’s Covid vaccine candidate Covaxin is set to undergo human clinical trials in July. It was developed at the firm’s Genome Valley plant in Hyderabad, in collaboration with the Indian Council of Medical Research (ICMR).
On Monday, the Hyderabad-based firm said the Drug Controller General of India gave the green light for phase-1 and phase-2 human clinical trials of the indigenously developed drug, following submission of results generated from pre-clinical (animal) studies. These were meant to demonstrate safety and immune response.
The SARS-CoV-2 strain was isolated at National Institute of Virology (Pune), an institute under the ICMR, and transferred
